Gyre Therapeutics, Inc.GYRENASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank50
3Y CAGR+4.2%
5Y CAGR-10.0%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+4.2%/yr
vs -31.3%/yr prior
5Y CAGR
-10.0%/yr
Recent acceleration
Acceleration
+35.4pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $5.42M | +39.4% |
| 2024 | $3.88M | -16.2% |
| 2023 | $4.64M | -3.3% |
| 2022 | $4.79M | -37.5% |
| 2021 | $7.67M | -16.3% |
| 2020 | $9.16M | +6176.0% |
| 2019 | $146000.00 | -99.3% |
| 2018 | $21.47M | +67.2% |
| 2017 | $12.85M | +21.7% |
| 2016 | $10.55M | - |